The collaboration with Excedea has opened new opportunities for us. The resources from Eurostars have helped us accelerate our R&D and our inhouse development. Since we had previously worked together with Excedea, we could hit the ground running with little time spent on Mentice’s side to get a very successful outcome.
We are indeed grateful for being selected by the EU considering the tough competition. There is a significant unmet need for the treatment of these diseases and we have first-in-class potential. Excedea added one of their core capacities to make us win – a convincing narrative.